Menu
Search
|

Menu

Close
X

CytRx Corp CYTR.OQ (NASDAQ Stock Exchange Capital Market)

0.59 USD
-0.06 (-9.23%)
As of Nov 16
chart
Previous Close 0.65
Open 0.68
Volume 131,532
3m Avg Volume 19,003
Today’s High 0.68
Today’s Low 0.58
52 Week High 2.45
52 Week Low 0.58
Shares Outstanding (mil) 33.64
Market Capitalization (mil) 22.81
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.348
FY17
-1.558
FY16
-4.053
FY15
-5.821
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
65.16
20.58
Price to Book (MRQ)
vs sector
1.02
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-67.71
13.58
Return on Equity (TTM)
vs sector
-67.71
15.11

EXECUTIVE LEADERSHIP

Steven Kriegsman
Chairman of the Board, Chief Executive Officer, Since 2018
Salary: $825,000.00
Bonus: $450,000.00
Eric Curtis
President, Chief Operating Officer, Since 2018
Salary: --
Bonus: --
John Caloz
Chief Financial Officer, Since 2009
Salary: $350,000.00
Bonus: $100,000.00
David Haen
Vice President - Business Development, Since 2007
Salary: --
Bonus: --
Olivia Ware
Chief Commercial Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11726 San Vicente Blvd Ste 650
LOS ANGELES   CA   90049-5079

Phone: +1310.8265648

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

SPONSORED STORIES